Superior Planning, LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Superior Planning, LLC’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$34.1K	Buy	+45	New	+$34K	0.01%	497

Other funds holding REGN

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Superior Planning, LLC's REGN Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 45 shares worth $34.1K. The stake represents 0.01% of the portfolio and ranks #497 among its holdings.

1,038 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Superior Planning, LLC held 45 shares of Regeneron Pharmaceuticals worth $34.1K as of Q3 2026.
Regeneron Pharmaceuticals was a new Superior Planning, LLC position in Q3 2026.
Regeneron Pharmaceuticals made up 0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #497 holding.
1,038 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.